Our Services
Medical Information
Helpful Resources
Published on: 11/20/2026
Hyperlipidemia is the broader term, and high cholesterol is one version of it. Hyperlipidemia means too much fat in your blood, which covers LDL, total cholesterol, and triglycerides. You can have normal cholesterol and badly elevated triglycerides and still be hyperlipidemic. That distinction matters because treatment differs: very high triglycerides respond to fibrates, omega-3s, and alcohol or sugar reduction, while high LDL is usually a statin conversation.
The myth worth killing: that cutting dietary cholesterol (eggs, shrimp) reliably moves your numbers. For most people it barely does. Saturated fat, refined carbs, body weight, thyroid function, and genetics do far more. Which is why your next step depends on specifics, your exact lipid panel breakdown, family history of early heart attacks, blood pressure, A1c, and whether you smoke. Those feed a 10-year risk estimate that decides whether meds make sense at all. One red flag: triglycerides over 1,000 with severe abdominal pain, vomiting, or fever means pancreatitis, get to an ER. No remote answer substitutes for labs and an exam.
Last reviewed for medical accuracy 11-17-2026
Hyperlipidemia and high cholesterol are closely related terms, but they're not exactly the same thing. Understanding the difference can help you better manage your heart health.
High cholesterol refers specifically to elevated levels of cholesterol in your blood. Cholesterol is a waxy, fat-like substance your body needs to build cells, but too much can increase your risk of heart disease.
Hyperlipidemia is a broader term that means you have too many lipids (fats) in your blood. This includes:
Think of it this way: high cholesterol is a type of hyperlipidemia, but hyperlipidemia can involve more than just cholesterol problems.
Mixed hyperlipidemia is a specific condition where you have elevated levels of both cholesterol and triglycerides. This combination is particularly important to address because it significantly increases your risk of developing cardiovascular disease, heart attacks, and strokes.
People with mixed hyperlipidemia typically have:
Mixed hyperlipidemia can be caused by genetic factors, lifestyle choices, or underlying health conditions like diabetes or obesity. It's one of the most common forms of lipid disorders affecting adults.
If you're concerned about your cholesterol or lipid levels, there are several steps you can take:
Get tested: A simple blood test called a lipid panel can measure your cholesterol and triglyceride levels. Most adults should have this checked every 4-6 years, or more frequently if you have risk factors.
Consider a symptom check: If you're experiencing any unusual symptoms or want to better understand what's going on with your health, you might consider doing a free, online symptom check to gather more information before your doctor's visit.
Make lifestyle changes: Many cases of hyperlipidemia can be improved through:
Medication may be necessary: For some people, especially those with mixed hyperlipidemia or genetic forms of the condition, lifestyle changes alone aren't enough. Your doctor may prescribe medications like statins or fibrates.
You should speak to a doctor if:
Hyperlipidemia often has no symptoms, which is why regular screening is important. Early detection and treatment can significantly reduce your risk of serious cardiovascular complications. Don't wait for warning signs—be proactive about your heart health.
Hypercholesterolemia refers specifically to elevated blood cholesterol levels, while hyperlipidemia is a broader term encompassing elevated cholesterol, elevated triglycerides, or both. Understanding this distinction matters because treatment approaches differ based on which lipids are elevated.
Hypercholesterolemia describes isolated high cholesterol, whereas familial combined hyperlipidemia and mixed dyslipidemia involve multiple lipid abnormalities including elevated triglycerides alongside cholesterol elevation. What this means for you: your doctor may use different terminology depending on which blood fats are elevated, and this affects which medications are recommended.
Monoclonal antibodies targeting PCSK9 (such as tafolecimab and recaticimab) reduced LDL cholesterol by 45 to 53 percent compared to placebo in adults with high cholesterol or mixed lipid elevations. What this means for you: these newer injectable medications offer significant cholesterol-lowering options for people who do not reach goal cholesterol levels with diet and statins alone.
Studies in large population cohorts showed that statin medications lower LDL cholesterol and reduce cardiovascular disease events, heart attack deaths, and overall mortality. What this means for you: statins remain a cornerstone therapy for managing elevated cholesterol and reducing long-term cardiovascular risk.
Most human trials measure blood lipid levels and short-term cardiovascular outcomes, but it remains unclear whether blood cholesterol numbers fully predict individual tissue-level atherosclerosis risk, particularly across sex and age groups. What this means for you: knowing your cholesterol numbers is helpful, but additional factors beyond cholesterol values may influence your actual heart and arterial disease risk.
(References)
[S1] Woods A. High cholesterol (hyperlipidemia). Nursing. 2002 Jun;32(6):56-7. doi: 10.1097/00152193-200206000-00046.
PubMed: https://pubmed.ncbi.nlm.nih.gov/12189985/
DOI: https://doi.org/10.1097/00152193-200206000-00046
[S2] Mipomersen. Am J Cardiovasc Drugs. 2010;10(4):271-9. doi: 10.2165/11533460-000000000-00000.
PubMed: https://pubmed.ncbi.nlm.nih.gov/20653334/
DOI: https://doi.org/10.2165/11533460-000000000-00000
[S3] Nussbaumerová B, Rosolová H. [Epidemiology of hypercholesterolemia]. Vnitr Lek. 2018 Winter;64(1):30-37.
PubMed: https://pubmed.ncbi.nlm.nih.gov/29498873/
[S4] Koletzko B. 3.20 Hypercholesterolemia. World Rev Nutr Diet. 2022;124:362-367. doi: 10.1159/000517394. Epub 2022 Mar 3.
PubMed: https://pubmed.ncbi.nlm.nih.gov/35240652/
DOI: https://doi.org/10.1159/000517394
[S5] Loh WJ, Watts GF. The Inherited Hypercholesterolemias. Endocrinol Metab Clin North Am. 2022 Sep;51(3):511-537. doi: 10.1016/j.ecl.2022.02.006. Epub 2022 Jul 4.
PubMed: https://pubmed.ncbi.nlm.nih.gov/35963626/
DOI: https://doi.org/10.1016/j.ecl.2022.02.006
[S6] Liu W, Liang B, Zeng J, Meng J, Shi L, Yang S, Chang J, Wang C, Hu X, Wang X, Han N, Lu C, Li J, Wang C, Li H, Zhang R, Xing D. First Discovery of Cholesterol-Lowering Activity of Parthenolide as NPC1L1 Inhibitor. Molecules. 2022 Sep 23;27(19). doi: 10.3390/molecules27196270. Epub 2022 Sep 23.
PubMed: https://pubmed.ncbi.nlm.nih.gov/36234807/
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC9572688/
DOI: https://doi.org/10.3390/molecules27196270
[S7] Kamstrup PR. Lipoprotein(a) and familial hypercholesterolemia: Partners in crime in heritable hyperlipidemia. Atherosclerosis. 2023 Jan;365:25-26. doi: 10.1016/j.atherosclerosis.2022.12.009. Epub 2022 Dec 24.
PubMed: https://pubmed.ncbi.nlm.nih.gov/36642659/
DOI: https://doi.org/10.1016/j.atherosclerosis.2022.12.009
[S8] Keam SJ. Tafolecimab: First Approval. Drugs. 2023 Nov;83(16):1545-1549. doi: 10.1007/s40265-023-01952-y.
PubMed: https://pubmed.ncbi.nlm.nih.gov/37847461/
DOI: https://doi.org/10.1007/s40265-023-01952-y
[S9] Hernandez R, Li X, Shi J, Dave TR, Zhou T, Chen Q, Zhou C. Paternal hypercholesterolemia elicits sex-specific exacerbation of atherosclerosis in offspring. JCI Insight. 2024 Sep 10;9(17). doi: 10.1172/jci.insight.179291. Epub 2024 Sep 10.
PubMed: https://pubmed.ncbi.nlm.nih.gov/39253968/
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC11385100/
DOI: https://doi.org/10.1172/jci.insight.179291
[S10] Xu M, Wang Z, Zhang Y, Liu Y, Huang R, Han X, Yao Z, Sun J, Tian F, Hu X, Ma L, Lai C, Zhang X, Sheng J, Han Q, Jin C, Luo L, Zhao R, Li L, Xu B, Yin D, Luo S, Ge X, Liu Z, Yang P, Huang Z, Li T, Feng W, Wu Y, Ling Z, Ma L, Lv C, Deng C, Wei W, Wang Y, Yan L, Ge J, REMAIN-1 Investigators. Recaticimab Monotherapy for Nonfamilial Hypercholesterolemia and Mixed Hyperlipemia: The Phase 3 REMAIN-1 Randomized Trial. J Am Coll Cardiol. 2024 Nov 12;84(20):2026-2036. doi: 10.1016/j.jacc.2024.07.035. Epub 2024 Oct 9.
PubMed: https://pubmed.ncbi.nlm.nih.gov/39387764/
DOI: https://doi.org/10.1016/j.jacc.2024.07.035
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.